Allergy/Imm Medical News about mTOR Inhibitors

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy
Transplantation, 07/27/09

Monaco AP – Organ transplant recipients given mammalian target of rapamycin inhibitor (mTORi) have reduced incidence of de novo posttransplant malignancies (dNPTMs). Posttransplant Kaposi's sarcoma and nonmelanotic skin malignancies (NMSC) frequently undergo remission/regression after conversion to mTORi immunosuppression (IS), especially early, small, and low–grade lesions, whereas larger, aggressive, and metastatic skin tumors are less likely to respond.

<< Previous
Spores as infectious propagules of Cryptococcus neoformans

Next >>
Assessment of Belatacept-Mediated Costimulation Blockade Through...